Introduction
Malignant transformation and tumor progression requires the cell to initiate sustained proliferation, escape endogenous cell-cycle control and DNA-damage checkpoints, evade external inhibitory factors and senescence and resist cell death. This is achieved by a combination of genetic and epigenetic events affecting the cancer cell itself, in particular the activation of oncogenes and immortalizing pathways and the inactivation of tumor suppressor and anti-apoptotic genes. In recent years, however, it became evident that in order to give rise to a clinically relevant tumor, cancer cells require support from the tumor microenvironment (Hanahan main stromal cell populations contributing to tumor progression (Lorusso and Rüegg, 2008) . The formation of a tumor-associated vasculature, a process also referred to as tumor angiogenesis, -of tumor hypoxia (Kerbel, 2008) . Many molecular mediators and regulators of angiogenesis have been in elucidated in recent years, but our understanding of the functional relationship between angiogenic vessels and the cellular elements of the tumor microenvironment has remained marrow-derived cells present in the tumor microenvironment concur to promote and regulate to tumor angiogenesis (Lorusso and Rüegg, 2008) .
Bone marrow-derived cells promoting tumor angiogenesis
Over the past decade, efforts have been undertaken to phenotypically and functionally characterize bone marrowderived (BMD) cells recruiting to the tumor microenvironment and promoting tumor angiogenesis. Functional experiments have been performed in mice and correlative studies in human. The phenotypical and functional plasticity, two main features intrinsically associated with the nature of these cells, make these study and the interpretation of the results complex.
While tumor-mobilized myelomonocytic BMD cells have been globally considered to exert pro-angiogenic activities, one of the BMD cell populations and their role in angiogenesis have been functional aspects associated with myelomonocytic CD11b + BMD cells mobilized by and recruited to tumors.
Phenotypic heterogeneity of monocytes and tumor associated macrophages
Monocytes are released from bone marrow into the circulation and differentiate into macrophage at tissue sites. Macrophages present in the tumor microenvironment are referred to as tumor associated macrophages or TAM (Coffelt et al., 2010; Mantovani et al., 2008; Murdoch et al., 2008) (Fig. 1) . Monocytes can be clasand express the chemokine receptor CX3CR1, the integrin LFA-1 ( L 2), but lack expression of Ly6C, CCR2 and L-selectin. Resident monocytes patrol blood vessels, promote tissues remodeling and might differentiate into pro-angiogenic macrophages. One particular subset of circulating monocytes promoting tumor angiogenesis is the Tie2-expressing monocyte subset, or (Coffelt et al., 2010; De Palma et al., 2005; Gabrilovich and Nagaraj, 2009; Mantovani et al., 2008; Murdoch et al., 2008; Murdoch et al., 2007; Passlick et al., 1989; Pollard, 2009) and references herein.
Angiogenesis-associated BMD cells have heterogeneous and in part overlapping phenotypes while they circulate in the blood and these phenotypes can be further modulated once the cells reach the tumor microenvironment. A further complication in the and mice. Depending of their activating stimuli, recruited BMD effects. Several different BMD cell populations contributing to tumor angiogenesis have been characterized (Coffelt et al., 2010; Murdoch et al., 2008) . i) Endothelial cell progenitors, which incorporate into the vasculature and differentiate into mature endothelial cells.
-; CD133
+ myelomonocytic cells that accumulate at tumor sites and contribute to tumor angiogenesis in a VEGFR-1-dependent manner;
iii) VEGFR-1 (Passlick et al., 1989) .
Recently, a CD11c + HLA-DR + monocytic population termed vascular leukocytes, was reported to assemble into blood vessels in vivo expressing both endothelial and leukocytic/monocytic markers, , VE cadherin and Tie2 (Murdoch et al., 2008) . These observations raise the question of whether distinct monocyte/ macrophage subsets found in tumors represent distinct lineages or are rather different differentiation states originated from a common progenitor cell. expressing monocytes and blood-circulating resident monocytes share gene expression gene signatures suggesting common developmental relationships and shared functions (Pucci et al., 2009) .
human (Pollard, 2009 ).
Myeloid-derived suppressor cells (MDSC)
A particular class of BMD myeloid cells consists of cells with immunosuppressive functions also called myeloid-derived suppressor cells (MDSC) (Gabrilovich and Nagaraj, 2009 (Youn et al., 2008) in the mouse and CD11b
+ HLA-DR -in human (Ochoa et al., 2007) .
Other types of cells, including neutrophils, eosinophils or dendritic cells may also express many of these markers and are reported to promote tumor angiogenesis (Coffelt et al., 2010; Murdoch et al., 2008) 
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Tie2 expressing monocytes (TEM)
The close proximity of TEM to the tumor vasculature observed by De Palma and colleagues, suggested that TEM might contribute to the regulation of tumor angiogenesis. Selective depletion of TEM by a suicide gene approach in mouse tumor models resulted in reduced tumor angiogenesis without impact on the recruitment of TAM or neutrophils (De Palma et al., 2005) . This observation suggested that TEM are a sub-population of monocytes distinct from precursors of TAM. It was suggested that TEM stimulate angiogenesis by expressing the pro-angiogenic molecule bFGF (De Palma et al., 2005) . Angiogenic activity of TEM may also be modulated by hypoxia and other cues, in particular angiopoietin-2. Exposure to both hypoxia and angiopoietin-2 markedly suppresses the release of the potent anti-angiogenic cytokine IL-12 by human TEM, and the combined action of angiopoietin-2 and hypoxia inhicytokines with context-dependent pro-or anti-angiogenic activities (Murdoch et al., 2007) (Fig. 2 ).
Tumor-associated macrophages (TAM)
Whereas M1 macrophages are thought to suppress tumor growth by secreting cytotoxic agents, such as TNF, IL-12, reactive nitrogen (iNOS) and reactive oxygen species (ROS) , M2 macrophages are considered to promote tumor growth. M2 macrophages release a number of potent pro-angiogenic cytokines, such as VEGF-A, VEGF-C, TNF, IL-8 and bFGF and suppress the immune response through the secretion of immunosuppressive cytokines, including IL-10 and transforming growth factor (TGF-9) . Additionally, TAM secrete a large panel of proteases, including urokinase-type plasminogen activator (uPA), members of the matrix metalloproteinase family (MMP-2, -7, -9 and -12) and elastases, which can contribute to the angiogenic switch. In vitro, TAM express additional pro-angiogenic factors like interleukin-19 and cyclooxygenase-2 (COX2) (Dirkx et al., 2006) . Tumor hypoxia plays an important role in modulating TAM activity. TAM accumulate in hypoxic and peri-necrotic tumor regions. Hypoxic macrophages up-regulate hypoxia-inducible transcription factors (HIF) resulting in the increased transcription of a large panel of genes that regulate cell survival, cell metabolism and angiogenesis, including hepatocyte growth factor (HGF), VEGF, bFGF, tissue factor (TF) or MMP-12 (Dirkx et al., 2006) (Fig. 2) .
Myeloid-derived suppressor cells (MDSC)
in particular T lymphocyte activation, in vitro and in vivo (Gabrilovich and Nagaraj, 2009 ). Several mechanisms have been proposed to explain this immunosuppressive effect, including release of cytokines and nitric oxide (NO), generation of reactive oxygen species (ROS), and increase activity of L-arginase (Kusmartsev and Gabrilovich, 2006) . Cytokine-mediated immunosuppression involves MDSC-mediated increased production of type 2 cytokines by macrophages, such as IL-10 and TGF-, and the down-regulation of the production of type 1 cytokines such as IL-12, thereby promoting the emergence of a M2 tumor-promoting phenotype. Furthermore, MDSC can produce TGF-in response to IL-13 stimulation, which further reduces the cytotoxic activity of T-cells. MDSC also express several factors with direct tumor-promoting activity, such as IL-6, platelet-derived growth factor (PDGF) or granulocyte macrophage colony-stimulating factor (GM-CSF) (Sauer et al., 2001) . Arginase, inducible NO synthase (iNOS), ROS and COX-2 have been shown to play a critical role in mediating the immuno-suppressive activity of the MDSC (Gabrilovich and Nagaraj, 2009 ). Indeed, T-cell proliferation and activation depends on the availability of L-arginine which is the substrate for two enzymes, the inducible iNOS and arginase-I. MDSC express both enzymes at high levels (Gabrilovich and Nagaraj, 2009) resulting in a depletion of L-arginine in the microenvironment and consequently in an inhibition of T-cell function. ROS contribute to the immune tolerance of cytotoxic CD8 T-cells by altering antigen recognition (Nagaraj et al., 2007) . COX-2 is a key factor promoting the activation of MDSC and in regulating the expression of arginase-1 and iNOS. COX-2 mediates the production of prostaglandin E 2 (PGE 2 ), a potent positive regulator of tumor angiogenesis (Gabrilovich and Nagaraj, 2009 ). Thus, COX-2 coordinates the suppressive activity of MDSC and angiogenesis in the tumor microenvironment (Fig. 2 ).
Other myeloid cell subpopulations
While many studies have analyzed the role of TAM, MDSC and TEM in tumor angiogenesis, additional myeloid-derived cell populations may also contribute to this process, including neutrophils, eosinophils, mast cells and dendritic cells (DC) (Coffelt et al., 2010) . For some of these cells, the mechanism by which they mediate or modulate tumor angiogenesis has been addressed, and in part elucidated, while for others it remains elusive. Tumor-associated neutrophils are a major source of MMP9, along with macrophages or mast cells, and appear to promote angiogenesis by releasing matrix-sequestered angiogenic factors, such as VEGF. Alternatively, they may themselves release VEGF via a degranulation process postulated that similarly to TAM, tumor-associated neutrophils can be polarized in the tumor environment into N1 or N2 phenotypes, the latter being associated to a tumor-promoting activity. TGF-has et al., 2009) . Eosinophils and mast cells can release factors like bFGF, IL-6, IL-8, PDGF, TNF, TGF-and matrix-modifying proteases, in particular MMP9, with pro-angiogenci properties (Crivellato et al., 2008) . In eosinophils, VEGF secretion is observed shortly after IL-15 stimulation. DC are considered to play an important role responses. Recent evidence, however, indicates that DC might also contribute to tumor angiogenesis by releasing proangiogenic factors, like VEGF and IL-8, in response to hypoxia (Ricciardi et al., 2008) . Human tumor cells implanted together with immature DC have enhanced tumor vascularization and growth, while mature DC did not impact angiogenesis (Fig. 2) .
These observations, together with the intrinsic plasticity of BMD and the persistence of polarizing signals in the tumor microenvireaching the tumor microenvironment might eventually produce proangiogenic and pro-invasive factors promoting tumor progression.
Mobilization and recruitment of bone marrow-derived myeloid cells into tumors
Recruitment of BMD myeloid cells is a highly regulated process depending of chemo-attractant factors. CCL2, also known as monocyte chemotactic molecule-1 (MCP-1) and CCL5, also known as RANTES, are well-established chemo-attractants for myeloid cells tumors. The HIF-1-dependent chemokine CXCL12 (also known as stromal cell-derived factor-1, SDF-1), a ligand for the chemokine -+ VEGFR1 + hemangiocytes (Jin (IL-10 high /Il-12 low ). Nuclear overexpression of the p50 subunit resulted in the inhibition of NFgenes including TNF and IL-12 (Saccani et al., 2006) . However, phenotype with reduced tumor growth attributed to restored NF-B activity (Saccani et al., 2006) . Another group showed that IKK / NF-B activation was required to maintain the M2 TAM phenotype in a model of ovarian cancer. Many different cell surface receptors expressed in macrophages lead to the activation of the NF-B pathway, including toll-like receptor (TLR), IL-1 receptor (IL-1R) and TNF receptor 1 (TNFR-1) (Karin et al., 2006) . For example, IL-19 induces the production of tumor-promoting factors, including VEGF, IL-6 and TNF in co-cultures of macrophages and B16 melanoma cells via NF-B. In an ovarian cancer model, macrophages from -lysaccharide (LPS) in a murine cancer metastasis model induced a NF-B activation and secretion of TNF by myeloid cells resulting in increased metastasis formation. Recently, Kim et al., showed that activation of TLR2 and TLR6 (receptors for Gram-positive bacteria-derived lipoteichoic acid and lipoprotein, respectively) by the proteoglycan versican up-regulated in many human tumors, induced TNF secretion by myeloid cells and increased metastasis in a Lewis lung carcinoma model . Further studies are necessary to investigate which factors and pathways are critically involved in the long-term maintenance of M2 phenotype of TAM and their pro-tumoral activities.
Therapeutic implications
in preclinical models and clinical studies (Fig. 3) .
COX-2
There is solid epidemiological evidence demonstrating that the reduces the risk of developing cancers, in particular colorectal cancer (Ulrich et al., 2006) . The use of NASAIDs leads to a signifamilial adenomatous polyposis coli (APC), thereby decreasing the risk for progression to carcinoma (Steinbach et al., 2000) . These effects have been attributed to the inhibition of COX-2, the induprogression, the sustained inhibition of COX-2 activity in patients was associated with severe cardiovascular and thromboembolic complications and the notion of using COX-2 inhibitors for longterm treatment for cancer prevention was abandoned. Alternative
Tumor necrosis factor (TNF)
There is a clear association between TNF expression and risk of cancer development and progression (Balkwill, 2009 
Gr1
+ cell-mediated tumor angiogenesis (Shojaei et al., 2008) . Anti-Bv8 antibody treatment resulted in a + Gr1 + cell mobilization from the bone marrow. Placenta growth factor (PlGF), a VEGF-family member binding only to VEGFR-1, has been reported to contribute to the recruitment of myeloid cells into the tumor microenvironment (Fischer et al., 2007) . Blocking PlGF results in the inhibition of monocyte/macrophage recruitment to tumor sites, reduced tumor angiogenesis and tumor growth, in particular in combination with anti-VEGF therapy (Fischer et al., 2007) . The role of PlGF in tumor angiogenesis, and its value as potential therapeutic target, however, is matter of controversy (Bais et al., 2010; Van de Veire et al., 2010) . Of interest, inhibition of PlGF activity results in reduced formation of lung metastases (Bais et al., 2010) . MMP-9, besides being an essential mediator of the angiogenic switch through the release of matrix-bound VEGF at tumor sites, can also promote BMD cell mobilization though the release of c-Kit ligand (or stem cell factor) form bone marrow stromal cells (Heissig et al., 2002) . CSF-1 was reported to be a critical factor promoting breast cancer growth and metastasis by attracting monocytes to the turmor (Lin et al., 2001) . A selective small molecule kinase inhibitor of CSF1R (GW2580) in combination with the anti-VEGFR-2 antibody DC101 suppresses tumor growth myeloid cells (Pollard, 2009 ).
Regulation of activation of tumor-recruited bone marrow-derived myeloid cells
Hypoxia
One common condition present in solid tumor is hypoxia (generally < 1% pO2). Tumor cells exposed to hypoxia, adapt their activities by expressing genes promoting glycolytic metabolism, angiogenesis, cell motility, invasion and metastasis. Many of these adaptive responses are regulated by hypoxia-inducible factors (HIFs) (Giaccia et al.
/ heterodimeric transcription factors whose subunit is degraded in the presence of oxygen by prolyl hydoxylases (PHDs) -mediated hydroxylation and targeting to the proteasome (Giaccia et al. the expression of many genes promoting angiogenesis including VEGF, PDGF-9, bFGF, eNOS, PlGF, angiopoietin-2. In addition HIF regulates the expression of chemo-attractant factors (i.e. MCP-1, CSF-1, SDF-1) to recruit myeloid cells into tumor hypoxic areas (Liao and Johnson, 2007) .
Macrophage activation depends on signals originating from the surrounding microenvironment. The NF-B pathway is a key mediator of macrophage activation in response to diverse environmental stimuli (i.e. stress, infections) and cancer (Karin and Greten, 2005) . NF-B activation in TAM shapes their pro-tumoral activities, including the release of TNF, IL-6 and IL-19, which sustain tumor cell growth or survival. Macrophages may change their protumoral phenotype depending of surrounding factors, tumor type, tumor stage, thereby contributing to the angiogenic switch. The role of NF-B in the functional plasticity of TAM has been shown by several studies. Saccani et al., showed that defective of NF-B function favored the induction of the M2 macrophage phenotype of experimental tumors, including in the skin. TNF inhibitors, either -mab), have entered clinical testing in multiple cancers, including ovary, breast and kidney. In these studies involving patients with advanced cancer, treatment was usually safe and well tolerated. There was evidence of biological activity of these TNF inhibitors reduced CCL2 and IL-6 levels).
Interleukin-1 (IL-1)
IL-1 is also a potentially attractive target for anti-cancer therapies as in some models it is clearly involved in tumor growth and et al., 2006) . Since IL-1 also stimulates the immune response, it could have dual, anti-and pro-tumoral effects. IL-1 is often highly expressed in solid tumors and polymorphism in the gene encoding IL-1Ra, the natural endogenous inhibitor of IL-1, is associated with susceptibility to some cancers, including of the bladder and colon. There is today increasing interest in inhibiting IL-1 as anti-cancer therapy and the availability of a clinically-approved IL-1 antagonist, anakinra may open the way to clinical studies aimed at testing this therapeutic opportunity (Dinarello, 2010) .
CXCL12/CXCR4
molecular antagonists or peptides (e.g. CTCE-9908, AMD3100, RCP169), resulted in reduced tumor growth and metastasis in several experimental models, including breast, prostate and brain. growth (Redjal et al.
ted tumor growth after chemotherapy by blocking the recruitment of mobilized endothelial progenitor cells and abrogated tumor re-
CD11b
+ BMD cells into irradiated tumors (Kioi et al., 2010 (Wood et al., 2002) . We have shown that zoledronate acts on endothelial cells through the suppression of multiple, prenylation-dependent signaling pathways, including Ras-MAPK and PI 3K-Akt (Hasmim et al., 2007) . In a transgenic mouse model of cervical cancer, zoledronate suppressed tumor angiogenesis and tumor progression by reducing MMP-9 expression in monocytes, resulting in decreased VEGF bioavailability (Giraudo et al. zoledronate and other nitrogen-containing bisphosphonates may have anti-angiogenic effects in humans. Zoledronate treatment of cancer patients with bone metastases leads to a sustained reduction in serum levels of VEGF and PDGF. A transient reduction of circulating levels of bFGF and MMP-2 after zoledronate infusion was also reported. We have tumor model, zoledronate treatments altered the phenotype of circulating BMD cells, their recruitment to tumor and decreased tumor angiogenesis (Botta, manuscript in preparation). Since zoledronate and other aminobisphosphonates are widely used in the clinics in cancer patients (i.e. for bone metastases treatment in breast and prostate cancers), it will be important to design studies to further test their ability to impinge on BMD cell mobilization and recruitment to tumors.
Other drugs -tedin and linomide have been described inhibiting pro-tumoral activity TAM and/ or impaired monocytes differentiation. Several existing anticancer agents such as paclitaxel have been proposed to act, at least in part, by inhibiting TAM recruitment and function.
Outstanding questions
It is nowadays widely accepted that BMD myelomonocytic cells are mobilized and recruited by the tumor to promote tumor angiogenesis and tumor progression. Many molecules and pathways Possible therapeutic targets have been further studies and clinical trials are underway to assess the feasibility of targeting BMD cells for therapeutic purposes in cancer. Nevertheless, a number of questions have remained unanswered, and novel ones are emerging. We would like to conclude by mentioning two questions of utmost clinical relevance:
Where are BMD cells programmed to acquire pro-angiogenic activity? As mentioned above, the unraveling of the correlation between BMD cell phenotype and function remain key to the understanding of the functional biology of these cells. Are there committed BMD cell populations that once induced by tumor-derived signals develop into pro-angiogenic cells by activating pre-established prodifferentiation program giving rise to multiple phenotypically and functionally distinct sub-populations originating from one common BMD cell precursor? Where does this education take place? It is generally assumed that cells are mobilized from the bone marrow and educated in the tumor. This seems a logical interpretation of available experimental results. Aternatively it is possible that cells are programmed in the bone marrow to express pro-angiogenic activity and to acquire a give cell surface phenotype as they are mobilized from the bone marrow. This hypothesis, however, has not been thoroughly addressed yet. Such a possibility could have important implications to tumor biology and tumor progression, since programmed cells could reach distant organs with a fully active pro-angiogenic program and thereby possibly contributing to initiate angiogenesis at pre-metastatic sites or at sites of dormant metastases. Indeed CD11b + VEGFR-1 + myelomonocytic BMD cells have been reported to form the premetastatic niche, although their functional phenotype has not been investigated. If programming occurs before they form the pre-metastatic site, this could open the perspective of impinging on their angiogenic education before they reach the distant site.
Can BMD myelomonocytic cells be used as surrogate markers of angiogenesis? To date there are no validated biomarkers of angiogenesis that can be applied in the clinic to quantify tumor angiogenic treatments. Endothelial progenitor cells have been largely explored to this end (Sessa et al., 2008) . In contrast, BMD myelomonocytic cells have not been thoroughly investigated to this end. We have initiated experiments to address this question and + myelomonocytic cells in mice (Botta et al., manuscript in preparation) and in breast cancer patients (Laurent et al., 2011) compared to tumor-free mice and healthy donors, respectively. We have also cells in tumor-free mice, tumor-bearing mice and tumor-bearing mice in gene expression (F. Botta et al., manuscript in preparation) . A gene-expression-based approach to monitoring the angiogenic status of circulating myelomonocytic cells would be an attractive biomarkers angiogenesis and anti-angiogenic therapies.
Conclusion
Since the original work published by the late Jeffry Isner in 1997 and reporting progenitor endothelial cells released from the bone marrow and capable of promoting angiogenesis at distant sites (Asahara et al., 1997) , we have gained a large amount of knowl-, we have gained a large amount of knowledge on the role of BMD cells in promoting tumor angiogenesis among this wealth of information we ask the relevant questions to unravel key issues and to identify the critical factors that may eventually allow us to translate this knowledge into therapeutic strategies in patients. Close interactions between basic and preclinical cancer researchers, clinical oncologists and industry will be necessary to reach this goal.
